Judicious use of additional immunohistochemistry can facilitate the identification of the origin of tumors to rule out pleomorphic leiomyosarcoma (SMA, desmin, and h-caldesmon), pleomorphic rhabdomyosarcoma (desmin), pleomorphic liposarcoma (S-100, SMA).[9,12,15] In our case, some tumor cells were weakly positive for EMA, however, they were negative for cytokeratin, smooth muscle actin, desmin, S-100, melan-A, CD34, etc. Therefore, we could exclude such entities and finally diagnosed as undifferentiated pleomorphic sarcoma. The gene discussed is SMN1; the disease is pleomorphic rhabdomyosarcoma.